Bambuterol oral
- Drugs List
- Therapeutic Indications
- Dosage
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Oral formulations of bambuterol hydrochloride.
Drugs List
Therapeutic Indications
Uses
Reversible airways obstruction
Dosage
Adults
Initial dose: 10mg to 20mg once daily at bedtime.
The 10mg dose may be increased if necessary to 20mg after 1 to 2 weeks.
In patients who have previously tolerated beta-2 agonists well, the recommended starting dose, as well as maintenance dose, is 20mg.
Patients with Renal Impairment
In patients with moderate to severely impaired renal function (GFR < 50 ml/min), it is recommended that the starting dose of bambuterol should be halved. Further doses should be adjusted according to response.
Contraindications
Children under 18 years
Galactosaemia
Hypertrophic cardiomyopathy
Precautions and Warnings
Predisposition to hypokalaemia
Breastfeeding
Cardiac arrhythmias
Diabetes mellitus
First trimester of pregnancy
Glucose-galactose malabsorption syndrome
Hypertension
Hyperthyroidism
Hypokalaemia
Hypoxia
Ischaemic heart disease
Lactose intolerance
Narrow angle glaucoma
Pregnancy at term
Renal impairment - glomerular filtration rate below 50ml/minute
Severe hepatic impairment
Thyrotoxicosis
May decrease glucose tolerance in patients with diabetes mellitus
Contains lactose
Monitor blood glucose closely in patients with diabetes mellitus
Monitor serum K+ in patients on high dose steroids/xanthines/diuretics
Monitor serum potassium in hypoxic patients
Monitor serum potassium regularly in patients with severe asthma
Advise patient to report any chest pain
Advise patient to seek medical advice if asthma seems to be worsening
May reduce serum potassium levels
Pregnancy and Lactation
Pregnancy
Use bambuterol with caution during first trimester of pregnancy and at term.
Bambuterol should be used with caution at the end of pregnancy due to the tocolytic effect.
Animal studies have shown no teratogenic effects. Avaliable data following use in human pregnancy does not indicate an increased risk of teratogenic or developmental effects.
Maternal beta2-agonist treatment may result in transient hypoglycaemia in pre-term new-born infants.
Lactation
Use bambuterol with caution in breastfeeding.
The presence of bambuterol in human breast milk is unknown. The active metabolite of bambuterol is terbutaline, which is present in breast milk but the therapeutic dose is unlikely to have an effect on breastfed infants.
Side Effects
Agitation
Angioedema
Atrial fibrillation
Behavioural disturbances
Bronchospasm (paradoxical)
Cardiac arrhythmias
Collapse
Dizziness
Exanthema
Extrasystoles
Headache
Hyperactivity
Hyperglycaemia
Hypersensitivity reactions
Hypokalaemia
Hypotension
Muscular cramps
Myocardial ischaemia
Nausea
Palpitations
Restlessness
Sleep disturbances
Supraventricular tachycardia
Tachycardia
Tremor
Urticaria
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: February 2021
Reference Sources
Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 3rd edition (2015) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.
Summary of Product Characteristics: Bambec Tablets 10mg. AstraZeneca UK Ltd. Revised January 2017.
Summary of Product Characteristics: Bambec Tablets 20mg. AstraZeneca UK Ltd. Revised January 2017.
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.